je.st
news
Tag: merck announces
Merck Announces First-Quarter 2013 Financial Results
2013-05-01 13:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. 2013 First-Quarter Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.52 Worldwide Sales were $10.7 Billion, a Decrease of 9 Percent Primarily as a Result of Patent Expiries, and Including a 2 Percent Unfavorable Impact from Foreign Exchange Growth in Vaccines, Immunology, HIV, Animal Health and Consumer Care Products Received Breakthrough Therapy Designation for Lambrolizumab, an Investigational Candidate for Advanced Melanoma; Five Products Currently Under Regulatory Review Announced New $15 Billion Share Repurchase Program; Plans to Repurchase Approximately $7.5 Billion of Common Stock over the Next Twelve Months Revises 2013 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Revises GAAP EPS Range to $1.92 to $2.16 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2013. $ in millions, except EPS amounts FirstQuarter2013 FirstQuarter2012 Language: English Contact HTML: MerckMedia Contacts:Steve Cragle, 908-423-3461Kelley Dougherty, 908-423-4291orInvestor Contacts:Carol Ferguson, 908-423-4465Alex Kelly, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Announces New $15 Billion Share Repurchase Program
2013-05-01 12:58:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Companys expanded program now totals $16.1 billion WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors has authorized additional purchases of up to $15 billion of Mercks common stock for its treasury. The company expects to repurchase approximately $7.5 billion of common stock over the next 12 months, financed through a combination of debt issuance and operating cash flows, with the remainder to be repurchased over time with no time limit. Language: English Contact HTML: MerckMedia Contact:Steven Cragle, 908-423-3461ORInvestor Contact:Alex Kelly, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: program
share
billion
announces
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
2013-04-24 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Mercks investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types. Language: English Contact HTML: MerckMedia:Caroline Lapppetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
therapy
announces
designation
Merck Announces FDA Acceptance of New Drug Application for an Investigational Tablet Formulation of the Antifungal NOXAFIL (posaconazole)
2013-04-10 14:30:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION N.J. WHITEHOUSE STATION N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration (FDA). Language: English Contact HTML: MerckMedia:Pam Eisele, (908) 423-5042Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
application
drug
acceptance
Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet
2013-03-27 13:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational Timothy grass pollen (Phleum pratense) allergy immunotherapy tablet (AIT) has been accepted for review by the U.S. Food and Drug Administration (FDA). In March, the company also submitted a BLA to the FDA for its investigational ragweed pollen (Ambrosia artemisiifolia) AIT. Language: English Contact HTML: MerckMedia:Pam Eisele, (908) 423-5042Tracy Ogden, (267) 305-2301orInvestors:Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
license
acceptance
grass
Sites : [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »